MassChallenge Texas wraps up inaugural Houston cohort with top 3 startups and a surprise investment

Cha-ching

MassChallenge Texas named its top three startups of its inaugural Houston cohort and the Houston Angel Network made an unexpected investment. Courtesy of MassChallenge Texas

A new-to-Houston global accelerator program just concluded its inaugural cohort, naming three top startups and providing a platform for an unexpected prize — an investment.

MassChallenge Texas didn't originally intend to have monetary prizes for this first program, however, thanks to Houston Angel Network, one lucky startup is walking away from the program $40,000 richer.

HAN, one of Houston's oldest and most active group of angel investors, saw pitch decks from most of the companies in the cohort and then invited seven companies to pitch: Ask DOSS, Celise, DoBrain, NeuroRescue, Noleus Technologies, Sensytec, and Swoovy.

At the September 5 startup showcase event, HAN named Houston-based Sensytec as the winner of the $40,000 investment prize.

The night's other big winners were MassChallenge's top three startups, program: NeuroRescue, Noleus Technologies, and Sensytec, which were selected from the top six startups that were announced a couple weeks in advance.

HAN engaged with the MassChallenge group in a few ways — like mentorship or presenting — but managing director Stephanie Campbell says she knew she wanted to discuss investment opportunities from the very beginning.

"I just think it's really important that when a new group like MassChallenge or any other accelerator come into town that we find ways to fold them into our community and help them be successful," she tells InnovationMap.

All of this year's cohort will receive 18 months of free coworking space — six months at MassChallenge, six months at The Cannon, and six months at Station Houston — and the top three startups will receive automatic entry into another MassChallenge cohort. Because no one won a cash prize from MassChallenge directly, all of the startups are eligible to reapply for another program.

"We wanted to make sure that the companies that went through the shortened version of the program this year have the ability to apply next year to any other program," MassChallenge Texas' Houston managing director, Jon Nordby, says.

Next time around, MassChallenge Texas will likely have a longer program with money on the table. That money would be provided by the organization's corporate partners. The city of Houston has put forth $2.5 million to be dealt out over five years, and Houston-based Reliant Energy has become a central partner to MassChallenge.

"We believe in supporting organizations that are pushing the boundaries and really making an impact in the community as well as the economy and the industry," says Elizabeth Killinger, president at NRG Retail and Reliant.

Killinger says next year she expects Reliant to be just as if not more involved with the process. Campbell too says HAN is interested in continuing its work with MassChallenge, and even sees it setting an example for other angel investors to get involved too.

"We're just planting the seed for the next cohort," Campbell says.

MassChallenge Texas named six companies, which will each pitch at a final competition on September 5. Photo via greenstreetdowntown.com

MassChallenge Texas names top startups from its inaugural Houston cohort to move on to the final round

best in class

MassChallenge Texas revealed the cream of the crop from its first Houston cohort. The top six startups will now be judged in one final pitch competition on September 5.

"Each of the 25 startups in our first cohort have made incredible progress during this short program and are now better prepared to make impact in Houston, Texas, and beyond," says Jon Nordby, managing director of MassChallenge Texas in Houston, in a release. "It is our goal to strengthen the local ecosystem through a collaborative community that will attract innovators from around the world to Houston, and the Lone Star State."

The program, which began on July 26, accelerated 25 early-stage companies from around the world with mentorship, corporate partnerships, curriculum, and more. No equity was taken by the program and it's free for the selected companies to attend.

"It is an honor to support the inaugural MassChallenge Texas accelerator in Houston and the incredible journey these startups have been on," says Elizabeth Killinger, president of Reliant and NRG Retail, in a release. "We're excited to be part of the thriving startup culture in Houston, and we look forward to all that this program will continue to bring to our city."

A panel of judges selected the top six, and now they face off for a set of prizes, which will be revealed at the Houston Finale. According to a spokesperson, the judges ahead of the event will decide on the winning company or companies and delegate prizes as they see fit.

The companies involved with supporting the accelerator include: Southwest Airlines, TMAC, WeWork, Upstream, USAA, BAE Systems, Brex, BHP, Central Houston, City of Houston, Houston Texans, Ingram Micro, Lionstone Investments, Midway, Reliant, San Antonio Spurs, Winstead Attorneys. Event and media partners are Insperity, Mattress Firm, Southwest Research Institute, Juice Consulting and Texas Squared Startup Newsletter.

FloodFrame

Houston-based FloodFrame is a company that provides self-deploying flood protection devices for residential and commercial real estate properties. Read more about the company here.

Mak Studio

Another Houston company — Mak Studio — makes the top startups list. The company provides interior design efforts made easy.

Neuro Rescue Inc.

NeuroRescue Inc. is an Ohio-based company that improves the standard of care used to treat stroke, brain injury, and cardiac arrest to increase neurological outcome by up to forty percent.

Noleus Technologies Inc.

Houston-based Noleus Technologies Inc. — a member of the TMCx07 cohort — has created a solution that reduces swelling in the bowels after operation. The disposable device is inserted into the abdomen at the time of surgery, and folds up like a fan to be removed without another surgery.

Reveal Technologies

Another Houston-based medical device company making it into MC's top 6 companies is Reveal Technologies, which uses a dual camera technology to help the 17 million Americans who suffer from retinal diseases to improve their sight.

Sensytec Inc.

Last but not least is Houston-based Sensytec Inc. The company has a "smart concrete" technology that is making moves in the energy industry.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice team keeps CO2-to-fuel devices running 50 times longer in new study

Bubbling Up

In a new study published in the journal Science, a team of Rice University researchers shared findings on how acid bubbles can improve the stability of electrochemical devices that convert carbon dioxide into useful fuels and chemicals.

The team led by Rice associate professor Hoatian Wang addressed an issue in the performance and stability of CO2 reduction systems. The gas flow channels in the systems often clog due to salt buildup, reducing efficiency and causing the devices to fail prematurely after about 80 hours of operation.

“Salt precipitation blocks CO2 transport and floods the gas diffusion electrode, which leads to performance failure,” Wang said in a news release. “This typically happens within a few hundred hours, which is far from commercial viability.”

By using an acid-humidified CO2 technique, the team was able to extend the operational life of a CO2 reduction system more than 50-fold, demonstrating more than 4,500 hours of stable operation in a scaled-up reactor.

The Rice team made a simple swap with a significant impact. Instead of using water to humidify the CO2 gas input into the reactor, the team bubbled the gas through an acid solution such as hydrochloric, formic or acetic acid. This process made more soluble salt formations that did not crystallize or block the channels.

The process has major implications for an emerging green technology known as electrochemical CO2 reduction, or CO2RR, that transforms climate-warming CO2 into products like carbon monoxide, ethylene, or alcohols. The products can be further refined into fuels or feedstocks.

“Using the traditional method of water-humidified CO2 could lead to salt formation in the cathode gas flow channels,” Shaoyun Hao, postdoctoral research associate in chemical and biomolecular engineering at Rice and co-first author, explained in the news release. “We hypothesized — and confirmed — that acid vapor could dissolve the salt and convert the low solubility KHCO3 into salt with higher solubility, thus shifting the solubility balance just enough to avoid clogging without affecting catalyst performance.”

The Rice team believes the work can lead to more scalable CO2 electrolyzers, which is vital if the technology is to be deployed at industrial scales as part of carbon capture and utilization strategies. Since the approach itself is relatively simple, it could lead to a more cost-effective and efficient solution. It also worked well with multiple catalyst types, including zinc oxide, copper oxide and bismuth oxide, which are allo used to target different CO2RR products.

“Our method addresses a long-standing obstacle with a low-cost, easily implementable solution,” Ahmad Elgazzar, co-first author and graduate student in chemical and biomolecular engineering at Rice, added in the release. “It’s a step toward making carbon utilization technologies more commercially viable and more sustainable.”

A team led by Wang and in collaboration with researchers from the University of Houston also recently shared findings on salt precipitation buildup and CO2RR in a recent edition of the journal Nature Energy.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings